`2009 – February 2015
`
`35%
`
`30%
`
`25%
`
`20%
`
`15%
`
`10%
`
`5%
`
`0%
`2009
`
`2010
`
`2011
`
`2012
`
`2013
`
`2014
`
`Source: Ex. 2176, p. 2 (IMS)
`
`VIMPAT® Share Among Branded AEDs
`
`VIMPAT® Share Among All AEDs
`
`Jan–Feb
`2015
`
`Page 1 of 4
`
`Argentum Pharm. v. Research Corp. Techs., IPR2016-00204
`RCT EX. 2176 - 1/4
`
`
`
`VIMPAT® U.S. Dollar Sales and Share of Total AED Dollar Sales
`2009 – February 2015
`
`IMS Estimated Sales ($MM)
`VIMPAT®
`Branded AEDs
`All AEDs
`
`VIMPAT® Share
`Among Branded AEDs
`Among All AEDs
`
`2009
`
`2010
`
`2011
`
`2012
`
`2013
`
`2014
`
`$35.5
`$1,766.9
`$2,354.2
`
`$135.8
`$1,462.4
`$1,991.5
`
`$227.5
`$1,514.4
`$2,043.9
`
`$338.6
`$1,592.9
`$2,074.6
`
`$475.2
`$1,732.2
`$2,396.2
`
`$629.0
`$2,025.7
`$2,769.6
`
`2.0%
`1.5%
`
`9.3%
`6.8%
`
`15.0%
`11.1%
`
`21.3%
`16.3%
`
`27.4%
`19.8%
`
`31.1%
`22.7%
`
`Jan–Feb
`2015
`
`$114.9
`$360.8
`$482.4
`
`31.9%
`23.8%
`
`[1]
`[2]
`[3]
`
`[4]
`[5]
`
`Notes:
`I understand from counsel that UCB’s standard business practice for evaluating the performance of VIMPAT® in the AED marketplace is to
`"factor" sales information related to certain AEDs to determine dollar sales that are associated with epilepsy.
`VIMPAT® launched May 2009.
`
`Sources:
`[1], [2], [3]: Ex. 2176, p. 4 (IMS)
`[4] = [1] / [2]
`[5] = [1] / [3]
`
`Page 2 of 4
`
`Argentum Pharm. v. Research Corp. Techs., IPR2016-00204
`RCT EX. 2176 - 2/4
`
`
`
`AED Shares of Total U.S. Branded Sales Dollars Associated with Epilepsy Indications
`2009 – February 2015
`
`AED
`
`APTIOM
`BANZEL
`DEPAKOTE
`DEPAKOTE‐ER
`DILANTIN
`FYCOMPA
`KEPPRA‐IR
`KEPPRA‐XR
`LAMICTAL
`LAMICTAL‐XR
`LYRICA
`NEUROTONIN
`POTIGA
`QUDEXY XR
`SABRIL
`TEGRETOL
`TEGRETOL‐XR
`TOPAMAX
`TRILEPTAL
`TROKENDI XR
`VIMPAT
`ZONEGRAN
`Total
`
`2009
`
`
`1.1%
`5.1%
`7.3%
`3.5%
`
`26.0%
`4.8%
`12.5%
`0.7%
`3.3%
`0.6%
`
`
`0.1%
`1.4%
`3.0%
`21.1%
`6.5%
`
`2.0%
`1.0%
`100.0%
`
`2010
`
`
`2.9%
`4.5%
`4.1%
`4.2%
`
`23.7%
`9.9%
`11.2%
`4.8%
`4.1%
`0.8%
`
`
`1.0%
`1.7%
`2.5%
`7.8%
`6.3%
`
`9.3%
`1.3%
`100.0%
`
`2011
`
`
`4.1%
`4.1%
`3.1%
`3.9%
`
`18.3%
`10.0%
`9.7%
`7.0%
`4.4%
`0.7%
`
`
`1.7%
`1.6%
`2.2%
`6.6%
`6.4%
`
`15.0%
`1.3%
`100.0%
`
`2012
`
`
`5.4%
`3.3%
`2.1%
`3.3%
`
`16.2%
`5.8%
`8.6%
`9.6%
`4.5%
`0.5%
`0.2%
`
`2.1%
`1.3%
`2.1%
`5.5%
`7.1%
`
`21.3%
`1.2%
`100.0%
`
`2013
`
`
`6.4%
`2.8%
`1.9%
`2.5%
`
`14.7%
`5.2%
`7.9%
`6.0%
`5.1%
`0.4%
`0.5%
`
`5.4%
`1.1%
`2.1%
`5.0%
`4.2%
`0.1%
`27.4%
`1.3%
`100.0%
`
`2014
`
`0.7%
`7.1%
`2.5%
`1.7%
`2.1%
`0.7%
`12.5%
`4.4%
`6.5%
`4.3%
`5.5%
`0.4%
`0.3%
`0.0%
`7.6%
`1.0%
`2.0%
`3.9%
`3.3%
`1.2%
`31.1%
`1.3%
`100.0%
`
`Jan–Feb
`2015
`
`1.7%
`7.3%
`2.1%
`1.5%
`1.9%
`1.1%
`10.9%
`4.0%
`6.4%
`4.2%
`5.5%
`0.3%
`0.2%
`0.0%
`9.1%
`0.9%
`1.9%
`3.3%
`3.0%
`1.7%
`31.9%
`1.3%
`100.0%
`
`Notes:
`I understand from counsel that UCB’s standard business practice for evaluating the performance of VIMPAT® in the AED marketplace is to
`"factor" sales information related to certain AEDs to determine dollar sales that are associated with epilepsy.
`VIMPAT® launched May 2009.
`
`Source:
`Ex. 2176. p. 4 (IMS)
`
`Page 3 of 4
`
`Argentum Pharm. v. Research Corp. Techs., IPR2016-00204
`RCT EX. 2176 - 3/4
`
`
`
`AED U.S. Sales Dollars Associated with Epilepsy Indications
`2009 – February 2015
`($ millions)
`
`2009
`
`2010
`
`2011
`
`2012
`
`2013
`
`2014
`
`Jan–Feb
`2015
`
`
`$19.4
`$90.8
`$128.2
`$62.2
`
`$459.0
`$85.3
`$220.2
`$13.1
`$57.6
`$10.9
`
`
`$1.2
`$24.1
`$52.8
`$373.5
`$115.2
`
`$35.5
`$18.0
`
`$38.7
`$83.2
`$76.0
`$155.9
`
`$36.5
`
`$14.5
`$15.2
`$82.8
`$28.1
`
`$44.4
`$12.1
`
`
`$42.1
`$65.2
`$60.6
`$61.3
`
`$345.9
`$144.7
`$164.5
`$70.0
`$60.5
`$11.2
`
`
`$15.2
`$24.2
`$36.4
`$113.5
`$92.3
`
`$135.8
`$19.1
`
`$50.0
`$38.3
`$67.6
`$155.9
`
`$13.0
`
`$16.7
`$14.6
`$99.3
`$13.7
`
`$47.3
`$12.6
`
`
`$61.7
`$61.4
`$46.2
`$58.6
`
`$277.5
`$150.8
`$146.6
`$106.6
`$66.2
`$10.9
`
`
`$25.7
`$23.5
`$33.6
`$100.0
`$97.5
`
`$227.5
`$20.0
`
`$52.8
`$26.1
`$62.7
`$171.2
`$4.5
`$13.1
`
`$20.8
`$16.1
`$99.4
`$12.1
`
`$39.9
`$10.8
`
`
`$85.8
`$51.8
`$34.2
`$53.2
`
`$258.8
`$92.4
`$136.7
`$152.6
`$71.1
`$7.5
`$3.8
`
`$32.8
`$20.3
`$32.7
`$87.9
`$113.3
`
`$338.6
`$19.4
`
`$35.6
`$22.0
`$48.1
`$169.4
`$12.7
`$10.8
`
`$19.1
`$16.2
`$95.2
`$11.3
`
`$32.0
`$9.2
`
`
`$110.4
`$48.3
`$32.9
`$43.4
`
`$254.2
`$89.7
`$136.1
`$104.5
`$88.7
`$7.0
`$8.9
`
`$93.6
`$18.4
`$37.1
`$86.0
`$73.6
`$2.4
`$475.2
`$21.8
`
`$36.1
`$90.8
`$48.6
`$163.8
`$15.4
`$11.3
`$86.6
`$17.6
`$16.8
`$103.3
`$10.5
`
`$42.4
`$20.9
`
`$14.3
`$144.8
`$50.9
`$35.0
`$42.4
`$14.6
`$252.3
`$89.9
`$132.7
`$86.8
`$111.4
`$7.1
`$5.4
`$0.0
`$153.7
`$19.7
`$39.9
`$79.6
`$67.5
`$23.4
`$629.0
`$25.4
`
`$42.4
`$132.2
`$59.2
`$157.5
`$17.4
`$12.0
`$82.6
`$17.3
`$49.4
`$102.4
`$10.4
`$0.2
`$43.7
`$17.1
`
`$1,766.9
`$587.4
`$2,354.2
`
`$1,462.4
`$529.1
`$1,991.5
`
`$1,514.4
`$529.5
`$2,043.9
`
`$1,592.9
`$481.7
`$2,074.6
`
`$1,732.2
`$664.0
`$2,396.2
`
`$2,025.7
`$744.0
`$2,769.6
`
`75%
`25%
`
`73%
`27%
`
`74%
`26%
`
`77%
`23%
`
`72%
`28%
`
`73%
`27%
`
`$6.2
`$26.4
`$7.5
`$5.3
`$6.7
`$3.8
`$39.3
`$14.4
`$23.0
`$15.0
`$19.8
`$1.2
`$0.8
`$0.2
`$32.7
`$3.2
`$6.9
`$11.9
`$10.7
`$6.2
`$114.9
`$4.6
`
`$8.3
`$17.4
`$12.0
`$24.8
`$2.4
`$1.8
`$12.9
`$2.8
`$13.1
`$15.4
`$1.4
`$0.2
`$6.8
`$2.2
`
`$360.8
`$121.6
`$482.4
`
`75%
`25%
`
`Branded AED Sales
`APTIOM
`BANZEL
`DEPAKOTE
`DEPAKOTE‐ER
`DILANTIN
`FYCOMPA
`KEPPRA‐IR
`KEPPRA‐XR
`LAMICTAL
`LAMICTAL‐XR
`LYRICA
`NEUROTONIN
`POTIGA
`QUDEXY XR
`SABRIL
`TEGRETOL
`TEGRETOL‐XR
`TOPAMAX
`TRILEPTAL
`TROKENDI XR
`VIMPAT
`ZONEGRAN
`
`Generic AED Sales
`Generic DEPAKOTE
`Generic DEPAKOTE‐ER
`Generic DILANTIN
`Generic KEPPRA‐IR
`Generic KEPPRA‐XR
`Generic LAMICTAL
`Generic LAMICTAL‐XR
`Generic NEUROTONIN
`Generic TEGRETOL
`Generic TEGRETOL‐XR
`Generic TOPAMAX
`Generic TOPIRAMATE ER
`Generic TRILEPTAL
`Generic ZONEGRAN
`
`Total Sales
`Total Branded
`Total Generic
`Grand Total
`
`Share of Sales
`Branded AEDs
`Generic AEDs
`
`Notes:
`I understand from counsel that UCB’s standard business practice for evaluating the performance of VIMPAT® in the AED marketplace is to "factor"
`sales information related to certain AEDs to determine dollar sales that are associated with epilepsy.
`VIMPAT® launched May 2009.
`
`Source:
`Ex. 2136 (IMS)
`
`Page 4 of 4
`
`Argentum Pharm. v. Research Corp. Techs., IPR2016-00204
`RCT EX. 2176 - 4/4